CD63 and Alzheimer disease: The CD63 levels of clinical samples in each group were analyzed by ELISA, and no significant differences were found among the AD, MCI and CON samples (Figure S17, Supporting Information), indicating that the Exo‐Aβ42 biomarkers were assessed under the assumption that exosomal CD63 levels did not vary among clinical samples.